MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Spark Therapeutics Company Profile (NASDAQ:ONCE)

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $53.71 (1.28% downside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2016Cowen and CompanyReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016WedbushReiterated RatingUnderperform$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2016Chardan CapitalReiterated RatingNeutral$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Evercore ISIInitiated CoverageBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageBuy -> Neutral$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016SunTrustInitiated CoverageBuy$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/24/2015WunderlichDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/11/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit SuisseInitiated CoverageOutperform$76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Sanford C. BernsteinInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2015Rodman & RenshawInitiated CoverageBuy$71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/24/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha